A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

NCT01673737 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Malignant

Interventions

DRUG: SAR260301
DRUG: Vemurafenib

Sponsor

Sanofi